No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NARI240517C90000
- 1.85
- 0.000.00%
15min DelayTrading Dec 21 11:05 ET
0.00High0.00Low
0.00Open1.85Pre Close0 Volume5 Open Interest90.00Strike Price0.00Turnover580.67%IV102.18%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry1.85Time Value100Contract SizeAmericanOptions Type0.1721Delta0.0101Gamma24.56Leverage Ratio-0.9008Theta0.0006Rho4.23Eff Leverage0.0111Vega
Intraday
- 5D
- 1D
News
Inari Medical: A Strong Buy on Growth and Market Expansion Potential
Novo Nordisk, Flagship to Develop Next-generation Obesity Drugs
Inari Medical to Participate in the 2024 Bank of America Securities Healthcare Conference
IRVINE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other
Director William Hoffman Sells Shares of Inari Medical Inc (NARI)
Inari Medical(NARI.US) Director Sells US$1.62 Million in Common Stock
$Inari Medical(NARI.US)$ Director Hoffman William sold 38,549 shares of common stock on May 1, 2024 at an average price of $42 for a total value of $1.62 million.Source: Announcement What is statement
Inari Medical Insider Sold Shares Worth $1,619,047, According to a Recent SEC Filing
William Hoffman, Director, on May 01, 2024, sold 38,549 shares in Inari Medical (NARI) for $1,619,047. Following the Form 4 filing with the SEC, Hoffman has control over a total of 965,359 shares of t
Comments
CEO Drew Hykes attributes Q4's robust revenue growth to healthy VTE procedure volumes, emerging therapies' traction, and strong international performance. He also highlights progress across all RCTs and the U.S. launch of LimFlow, emphasizing commitment to strong growth and operating profitability.
Press Release: Inari Medical Announces Preliminary 2023 Revenue and 2024 GuidanceThe appointment of Rhonda Robb, with her extensive experience and proven track record, is expected to lead Okami Medical into its next phase of expansion and growth, particularly as the company prepares to commercialize its LOBO Vascular Occlusion System.
The increased insider selling of Inari Medical stock over buying in the last three months along with the year-long trend of insider transactions indicate caution despite high insider ownership. Company risk factors should also be considered alongside insider behavior.
The future looks bleak with predicted negative returns; current investors should consider de-risking. For potential investors, a negative growth outlook raises the risk of holding the Inari Medical stock. Careful examination of further insights and warning signs is advised before investing.
Upgrades
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
16
Read more